Drug Approval | April 28, 2025
Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
A new weapon in the global fight against malaria
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Rising demands and advancements in eye care drive growth
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Subscribe To Our Newsletter & Stay Updated
